文献速递免疫规划传染病防控与疫情报告

重组融合蛋白亚单位疫苗可有效保护大口黑鲈抵抗传染性脾肾坏死病毒感染

Development of a recombinant fusion protein subunit vaccine comprising two truncated proteins effectively protects largemouth bass against infectious spleen and kidney necrosis virus infection.
PubMed 文献 · Vaccine · 2025-11-29

本研究针对传染性脾肾坏死病毒(ISKNV)主要衣壳蛋白(MCP)亚单位疫苗保护效果不足的问题,通过生物信息学筛选出富含抗原表位的截短蛋白tMCP和t051L,经刚性连接肽连接构建融合截短蛋白t051L-tMCP,并用原核表达系统诱导纯化。腹腔注射免疫大口黑鲈后,血清抗体滴度在28天内随时间逐渐升高,1 mg/mL免疫剂量下保护效果最佳:tMCP组和t051L组存活率分别为85.01%和79.01%,t051L-tMCP组存活率显著达95.50%,优于两单独蛋白组。攻毒后7天病毒载量检测显示,免疫鱼头肾、肝脏和脾脏组织病毒复制显著低于PBS组,且免疫检测结果呈明显剂量依赖关系。

要点

  • 融合截短蛋白t051L-tMCP免疫后存活率达95.50%,优于tMCP(85.01%)和t051L(79.01%)单独免疫。
  • 1 mg/mL为最佳免疫剂量,血清抗体滴度在免疫后28天内随时间逐渐升高。
  • t051L-tMCP显著降低攻毒后7天头肾、肝脏和脾脏组织病毒载量,免疫保护呈剂量依赖。

核心结论

  • 融合截短蛋白t051L-tMCP具有优良免疫原性,较tMCP和t051L显著增强免疫保护能力。
  • t051L-tMCP可作为预防传染性脾肾坏死病毒病的有效候选重组融合截短蛋白疫苗。

研究设计与样本

  • 研究采用生物信息学分析ISKNV MCP和候选蛋白051L序列并预测功能,筛选富含抗原表位的截短蛋白tMCP和t051L,经刚性连接肽连接构建融合截短蛋白t051L-tMCP。
  • tMCP、t051L和t051L-tMCP通过原核表达系统诱导纯化,以腹腔注射方式免疫大口黑鲈,评估不同蛋白的免疫原性和保护效力。

主要发现

  • 血清ELISA结果显示,所有免疫组血清抗体滴度在免疫后28天内随时间逐渐升高。
  • 1 mg/mL免疫剂量下保护效果最佳:tMCP组存活率为85.01%,t051L组为79.01%,t051L-tMCP组存活率显著达95.50%,优于tMCP和t051L组。
  • 攻毒后7天病毒载量检测显示,免疫鱼头肾、肝脏和脾脏组织病毒复制显著低于PBS组。
  • 免疫检测结果呈明显剂量依赖关系。

关键数值与推荐

  • 最佳免疫剂量为1 mg/mL;该剂量下t051L-tMCP组存活率95.50%,tMCP组85.01%,t051L组79.01%。
  • 血清抗体滴度在免疫后28天内随时间逐渐升高。
  • 攻毒后7天检测头肾、肝脏和脾脏组织病毒载量,免疫组显著低于PBS组。

临床怎么用

  • t051L-tMCP融合截短蛋白可作为预防ISKNV感染的候选疫苗,推荐1 mg/mL剂量腹腔注射免疫。
  • 免疫后28天内血清抗体滴度随时间升高,提示该窗口期需关注抗体动态以评估免疫效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The infectious spleen and kidney necrosis virus (ISKNV) is a major pathogen causing infectious spleen and kidney necrosis disease in largemouth bass. As its major capsid protein (MCP) is considered a candidate subunit vaccine, its protective efficacy in practical applications remains suboptimal, failing to meet clinical prevention and control demands. This study employed bioinformatics techniques to analyze the sequences and predict the functions of MCP and candidate protein 051 L of ISKNV. Two truncated proteins (designated tMCP and t051L) with rich antigenic epitope were screened, which were linked via a rigid linker peptide to construct the fusion truncated protein t051L-tMCP. tMCP, t051L, and t051L-tMCP were induced and purified by using the prokaryotic expression system. The immunogenicity and protective efficacy of the different proteins were evaluated by intraperitoneal injection. Serum ELISA results showed that serum antibody titers in all immunized groups gradually increased with time within 28 days post-immunization. Simultaneously, optimal protection was achieved at an immunization dose of 1 mg/mL: The survival percentages of fish in the tMCP group and in the t051L group were 85.01 % and 79.01 %, while the t051L-tMCP group demonstrated a significantly survival percentages of 95.50 %, superior to the tMCP and t051L groups. Furthermore, viral load detection 7 days post-challenge revealed significantly reduced viral replication in the head kidney liver, and spleen tissues of vaccinated fish compared to the PBS group. Above all, a clear dose-dependent relationship was also observed in the immunoassay results. Consequently, immunological studies demonstrate that the fusion protein t051L-tMCP exhibits excellent immunogenicity. Furthermore, t051L-tMCP significantly enhances the immune protective capacity compared to tMCP and t051L. Our study provides an efficient and viable recombinant fusion truncated protein candidate vaccine for the prevention of infectious spleen and kidney necrosis virus disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhang X, Xu T, Xian J, et al. Development of a recombinant fusion protein subunit vaccine comprising two truncated proteins effectively protects largemouth bass against infectious spleen and kidney necrosis virus infection. Vaccine. 2025. PMID: 41319440. doi:10.1016/j.vaccine.2025.128007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。